Development of a Novel Anti-HIV Oligonucleotide
1 R43 AI38788-01,
AIDS is a fatal disorder of the immune system caused by the HIV and is a widespread epidemic. The lobjective of this work is to treat human AIDS patients with a novel oligonucleotide (T30177) that haanti-HIV activity. We will perform preclinical animal pharmacology studies, including pharmacokinetiand toxicity studies in mice. One of these aims includes investigating a novel in vivo route of admioligonucleotides. Although there are a number of drugs that are currently available for the treatmenhave limited effectiveness and only delay the progression to death of AIDS patients. There is a greadevelopment of more effective and novel drugs for the treatment of AIDS. T30177 may provide significpresently available HIV drugs because it has a novel mechanism of action, it is active against AZT-rbeen shown in pilot animal studies to have a long half-life, good stability, and low toxicity.
Small Business Information at Submission:
Principal Investigator:Thomas Wallace
9391 Grogans Mill Road The Woodlands, TX 77380
Number of Employees: